甲氨蝶呤单药治疗类风湿关节炎缓解率低:随机对照试验综述或指向范式转变
该综述指出,尽管甲氨蝶呤仍是类风湿关节炎(RA)的锚定药物和一线治疗,但多项随机对照试验比较显示,生物制剂DMARDs和靶向合成DMARDs在早期和已确立RA中疗效均优于甲氨蝶呤,甲氨蝶呤单药仅使最多半数患者达到缓解。综述提示可能需范式转变,即更早启用生物制剂或靶向合成DMARDs,并在获得稳定缓解后考虑停药,但策略试验尚未显示明确优势,需进一步研究确认。
要点
- 甲氨蝶呤单药治疗RA的缓解率最高仅达半数患者。
- 生物制剂和靶向合成DMARDs疗效一致优于甲氨蝶呤。
- 早期强化治疗策略的明确优势尚未被策略试验证实。
核心结论
- 甲氨蝶呤单药治疗的缓解率有限,可能支持更早启用生物制剂或靶向合成DMARDs的范式转变。
- 策略试验未显示初始强化治疗策略的明确优势,未来需进一步研究确认。
研究设计与样本
- 本文为综述,汇总比较甲氨蝶呤与生物制剂DMARDs及靶向合成DMARDs的随机对照试验及策略试验。
主要发现
- 在早期和已确立RA中,生物制剂DMARDs和靶向合成DMARDs疗效一致优于甲氨蝶呤。
- 甲氨蝶呤单药使最多半数患者达到缓解。
- 策略试验显示初始强化治疗可能有临床和结构获益,甚至可能提高停用生物制剂DMARD后单用甲氨蝶呤维持缓解的几率,但未显示明确优势。
关键数值与推荐
- 甲氨蝶呤单药治疗达到缓解的患者比例最高为半数。
临床怎么用
- 可考虑对部分RA患者更早启用生物制剂或靶向合成DMARDs,并在获得稳定缓解后尝试停药。
- 应重视糖皮质激素作为联合策略组成部分的作用,策略试验应将其作为活性对照。
局限性
- 更早启用生物制剂或靶向合成DMARDs的范式转变尚需未来研究进一步确认。
- 策略试验未显示初始强化治疗的明确优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of rheumatoid arthritis (RA) has improved substantially during the last decades, mainly due to the development and introduction in everyday practice of new, highly efficacious, disease-modifying antirheumatic drugs (DMARDs), more optimal usage of them, earlier diagnosis and tighter control of disease activity targeting at remission. Methotrexate is still today the anchor drug and the first-line treatment after diagnosis. However, numerous studies comparing methotrexate and biologic DMARDs, as well as new targeted synthetic DMARDs, both in early as in more established disease, have shown consistently better efficacy of the latter compared with methotrexate, with methotrexate yielding remission to maximum half of patients. This could suggest a new paradigm shift with earlier start of a biologic or a targeted synthetic DMARD, with the possibility of subsequent discontinuation in case of achievement of stable remission. Several strategy trials, however, have shown that there might be a clinical and structural benefit of initial, aggressive therapy, possibly even associated with higher chance of remaining in remission, after cessation of the biologic DMARD and continuing with methotrexate alone, but they have failed to show a clear advantage of such an aggressive treatment strategy. This might become a valuable option for the future treatment algorithm of RA, especially for a subgroup of patients with RA, but further confirmation from future research is needed. The crucial role of glucocorticoid use as part of the combination strategy should be acknowledged, and strategy trials should include this combination as an active comparator.
引用
- Chatzidionysiou K, Sfikakis PP. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019. PMID: 31413870. doi:10.1136/rmdopen-2019-000993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。